Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Dengue Vaccines
April 12, 2022
Despite being the first and only marketed dengue vaccine, Dengvaxia use has been limited due to major safety concerns. The dengue vaccines market is however expected to expand rapidly following the anticipated approval of TAK-003 in approximately mid-2022 to early 2023. The pipeline remains active, with two late-phase live-attenuated vaccines (LAVs), Takeda’s TAK-003 and Merck & Co’s TV003/TV005, in development in dengue-endemic regions. TV003/TV005 was initially developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and has been licensed to the Butantan Institute in Brazil, where it is in Phase III trials; Merck & Co in the US, Canada, China, Europe, and Japan; and various other developers in India, the Middle East, and Asia-Pacific markets, with the goal of ensuring market access by facilitating cheaper domestic production in key dengue-endemic regions.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Dengue Fever - Vaccines and Treatments|